Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Dis Markers ; 2020: 8829373, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32963638

RESUMO

OBJECTIVES: Congenital diaphragmatic hernia (CDH) is a birth defect affecting the respiratory functions, functional performance, and quality of life (QOL) in school-aged children. Rarely have studies been conducted to evaluate the impacts of respiratory muscle training on school-aged children with postoperative CDH. The current study was designed to evaluate the impacts of respiratory muscle training on respiratory function, maximal exercise capacity, functional performance, and QOL in these children. METHODS: This study is a randomized control study. 40 children with CDH (age: 9-11 years) were assigned randomly into two groups. The first group conducted an incentive spirometer exercise combined with inspiratory muscle training (study group, n = 20), whereas the second group conducted only incentive spirometer exercise (control group, n = 20), thrice weekly for twelve consecutive weeks. Respiratory functions, maximal exercise capacity, functional performance, and pediatric quality of life inventory (PedsQL) were assessed before and after the treatment program. Results. Regarding the posttreatment analysis, the study group showed significant improvements in all outcome measures (FVC%, p < 0.001; FEV1%, p = 0.002; VO2max, p = 0.008; VE/VCO2 slope, p = 0.002; 6-MWT, p < 0.001; and PedsQL, p < 0.001), whereas the control group did not show significant changes (p > 0.05). CONCLUSION: Respiratory muscle training may improve respiratory functions, maximal exercise capacities, functional performance, and QOL in children with postoperative CDH. Clinical commendations have to be considered to include respiratory muscle training in pulmonary rehabilitation programs in children with a history of CDH.


Assuntos
Exercícios Respiratórios/métodos , Teste de Esforço/métodos , Hérnias Diafragmáticas Congênitas/reabilitação , Hérnias Diafragmáticas Congênitas/cirurgia , Espirometria/instrumentação , Criança , Terapia Combinada , Tolerância ao Exercício , Feminino , Hérnias Diafragmáticas Congênitas/fisiopatologia , Humanos , Masculino , Desempenho Físico Funcional , Qualidade de Vida , Resultado do Tratamento
2.
An Pediatr (Engl Ed) ; 91(4): 273.e1-273.e8, 2019 Oct.
Artigo em Espanhol | MEDLINE | ID: mdl-31495740

RESUMO

Survival of patients with congenital malformation has improved over the last decades. Primary care paediatricians must be aware of the most common problems that this group of patients suffers. More importantly, paediatricians can offer a holistic view that is often lost in specialised consultation. This article is focused on common congenital malformation, such as oesophageal atresia, abdominal wall defects, anorectal malformation and Hirschsprung disease, and congenital diaphragmatic hernia. The main problems are shown, with special emphasis on long-term complications and all the dimensions of the individual.


Assuntos
Parede Abdominal/anormalidades , Anormalidades do Sistema Digestório/terapia , Hérnias Diafragmáticas Congênitas/terapia , Atenção Primária à Saúde/métodos , Criança , Anormalidades do Sistema Digestório/fisiopatologia , Hérnias Diafragmáticas Congênitas/fisiopatologia , Doença de Hirschsprung/fisiopatologia , Doença de Hirschsprung/terapia , Humanos , Pediatria
3.
Am J Physiol Lung Cell Mol Physiol ; 311(4): L734-L742, 2016 Oct 01.
Artigo em Inglês | MEDLINE | ID: mdl-27521424

RESUMO

Patients with congenital diaphragmatic hernia (CDH) suffer from severe pulmonary hypertension attributable to altered development of the pulmonary vasculature, which is often resistant to vasodilator therapy. Present treatment starts postnatally even though significant differences in the pulmonary vasculature are already present early during pregnancy. We examined the effects of prenatal treatment with the phosphodiesterase-5 inhibitor sildenafil on pulmonary vascular development in experimental CDH starting at a clinically relevant time. The well-established, nitrofen-induced CDH rodent model was treated daily with 100 mg/kg sildenafil from day 17.5 until day 20.5 of gestation (E17.5-20.5). Importantly, this timing perfectly corresponds to the developmental stage of the lung at 20 wk of human gestation, when CDH is detectable by 2D-ultrasonography and/or MRI. At E21.5 pups were delivered by caesarean section and euthanized by lethal injection of pentobarbital. The lungs were isolated and subsequently analyzed using immunostaining, real-time PCR, and volume measurements. Prenatal treatment with sildenafil improved lung morphology and attenuated vascular remodeling with reduced muscularization of the smaller vessels. Pulmonary vascular volume was not affected by sildenafil treatment. We show that prenatal treatment with sildenafil within a clinically relevant period improves pulmonary vascular development in an experimental CDH model. This may have important implications for the management of this disease and related pulmonary vascular diseases in human.


Assuntos
Hérnias Diafragmáticas Congênitas/prevenção & controle , Inibidores da Fosfodiesterase 5/uso terapêutico , Citrato de Sildenafila/uso terapêutico , Remodelação Vascular/efeitos dos fármacos , Animais , Avaliação Pré-Clínica de Medicamentos , Feminino , Hérnias Diafragmáticas Congênitas/induzido quimicamente , Hérnias Diafragmáticas Congênitas/fisiopatologia , Pulmão/irrigação sanguínea , Pulmão/patologia , Exposição Materna , Troca Materno-Fetal , Éteres Fenílicos , Inibidores da Fosfodiesterase 5/farmacologia , Gravidez , Ratos Sprague-Dawley , Citrato de Sildenafila/farmacologia
4.
Am J Physiol Lung Cell Mol Physiol ; 310(7): L658-69, 2016 04 01.
Artigo em Inglês | MEDLINE | ID: mdl-26873974

RESUMO

Infants with congenital diaphragmatic hernia (CDH) fail to adapt at birth because of persistent pulmonary hypertension (PH), a condition characterized by excessive muscularization and abnormal vasoreactivity of pulmonary vessels. Activation of soluble guanylate cyclase by BAY 41-2272 prevents pulmonary vascular remodeling in neonatal rats with hypoxia-induced PH. By analogy, we hypothesized that prenatal administration of BAY 41-2272 would improve features of PH in the rabbit CDH model. Rabbit fetuses with surgically induced CDH at day 23 of gestation were randomized at day 28 for an intratracheal injection of BAY 41-2272 or vehicle. After term delivery (day 31), lung mechanics, right ventricular pressure, and serum NH2-terminal-pro-brain natriuretic peptide (NT-proBNP) levels were measured. After euthanasia, lungs were processed for biological or histological analyses. Compared with untouched fetuses, the surgical creation of CDH reduced the lung-to-body weight ratio, increased mean terminal bronchial density, and impaired lung mechanics. Typical characteristics of PH were found in the hypoplastic lungs, including increased right ventricular pressure, higher serum NT-proBNP levels, thickened adventitial and medial layers of pulmonary arteries, reduced capillary density, and lower levels of endothelial nitric oxide synthase. A single antenatal instillation of BAY 41-2272 reduced mean right ventricular pressure and medial thickness of small resistive arteries in CDH fetuses. Capillary density, endothelial cell proliferation, and transcripts of endothelial nitric oxide synthase increased, whereas airway morphometry, lung growth, and mechanics remained unchanged. These results suggest that pharmacological activation of soluble guanylate cyclase may provide a new approach to the prenatal treatment of PH associated with CDH.


Assuntos
Ativadores de Enzimas/farmacologia , Hérnias Diafragmáticas Congênitas/fisiopatologia , Hipertensão Pulmonar/tratamento farmacológico , Pirazóis/farmacologia , Piridinas/farmacologia , Anormalidades Múltiplas/tratamento farmacológico , Animais , Avaliação Pré-Clínica de Medicamentos , Ativadores de Enzimas/uso terapêutico , Feminino , Doenças Fetais/tratamento farmacológico , Guanilato Ciclase/metabolismo , Hérnias Diafragmáticas Congênitas/tratamento farmacológico , Pulmão/anormalidades , Pulmão/efeitos dos fármacos , Pulmão/patologia , Pneumopatias/tratamento farmacológico , Gravidez , Cuidado Pré-Natal , Pirazóis/uso terapêutico , Piridinas/uso terapêutico , Coelhos , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA